Tebotelimab

{
  "id": "MLC-T-ONC-017008",
  "term": "Tebotelimab",
  "field": "Oncology and biomedicine",
  "definition": "An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.",
  "synonyms": [
    "bispecific DART protein MGD013",
    "PD-1 x LAG-3 bispecific DART molecule MGD013",
    "PD-1 x LAG-3 DART molecule MGD013",
    "PD-1 x LAG-3 DART protein MGD013",
    "anti-PD-1/anti-LAG-3 DART protein MGD013",
    "dual-affinity retargeting protein MGD013"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tebotelimab/"
}